DSM proposes to use oligosaccharide compositions as microbiome metabolic therapies for treating inflammatory lung diseases and disorders, such as chronic obstructive pulmonary disease (COPD) and asthma.
See the original patent on Espacenet:
Oligosaccharide compositions and methods of use thereof for treating inflammatory lung diseases